ISRCTN70010120
Completed
Not Applicable
Does aldosterone blockade improve endothelial dysfunction in patients with coronary artery disease but without heart failure?
niversity of Dundee (UK)0 sites88 target enrollmentMarch 29, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary artery disease
- Sponsor
- niversity of Dundee (UK)
- Enrollment
- 88
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient with known coronary artery disease
- •2\. Chronic stable angina
Exclusion Criteria
- •1\. Left ventricular systolic dysfunction
- •2\. Renal failure
- •3\. Hyperkalaemia
- •4\. Warfarin therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)ADPKDNCT01853553University of Colorado, Denver61
Not yet recruiting
Phase 4
se of aldosterone blockade to improve cardiac function in obesityDiastolic DysfunctionMyocardial fibrosisCardiovascular - Other cardiovascular diseasesACTRN12609000655246The University of Queensland120
Completed
Not Applicable
Effects of aldosterone antagonism on microvascular function in obese individualsNL-OMON45212niversiteit Maastricht60
Completed
Not Applicable
Aldosterone-induced microvascular dysfunction as a cause of salt-sensitivity in obesity?insulin resistance/decreased sensitivity for insulinsalt-sensitivity of blood pressure1001842410057166NL-OMON40283Medisch Universitair Ziekenhuis Maastricht40
Recruiting
Phase 3
Evaluation of spironolactone on heart related mortality and morbidity among patients undergoing chronic kidney dialysisHealth Condition 1: N186- End stage renal diseaseCTRI/2019/06/019703Population Health Research Institute